AbVitro

AbVitro

AbVitro, a spinout from George Church’s lab at Harvard University.

HQ location
Boston, United States
Launch date
Enterprise value
$125m
  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round

$125m

Valuation: $125m

Acquisition
Total Funding000k
Notes (0)
More about AbVitro
Made with AI
Edit

AbVitro, a spinout from George Church’s lab at Harvard University, is a therapeutic target discovery company. It offers a technology platform that leverages natural immune responses to address diseases with unmet medical needs. The company's technology allows for the identification of full-length, natively paired antibodies and T cell receptors.

This technology is used to identify novel therapeutic targets and antibodies for cancer, autoimmune, and infectious diseases. The company's intellectual property includes 21 registered patents, primarily in the 'Medical or Veterinary Science; Hygiene' category.

AbVitro was acquired by Juno Therapeutics. Prior to the acquisition, the company was funded by Sante Ventures.

Keywords: therapeutic targets, antibody discovery, immune sequencing, cancer, autoimmune diseases, infectious diseases, T cell receptors, medical patents, Juno Therapeutics, Sante Ventures

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo